Article

Is post-PNL nephroscopy necessary? Medical therapy may be better option

Second-look nephroscopy following percutaneous nephrolithotomy(PNL) could be supplanted by metabolic evaluation and aggressive medicaltherapy, advise researchers from the Duke University Medical Center. Second-looknephroscopy is currently the gold standard for assessing and achieving stone-freestatus, but the Duke researchers sought to determine whether this additionalprocedure was necessary.

Related Videos
Perry Xu, MD, answers a question during a Zoom video interview
Helen L. Bernie, DO, MPH, answers a question during a Zoom video interview
Kate H. Kraft, MD, MHPE, FACS, FAAP, answers a question during a Zoom video interview
John P. Mulhall, MD, answers a question during a Zoom video interview
Related Content
Data reinforce isodose MHFRT as standard of care radiotherapy regimen
March 22nd 2025

Data reinforce isodose MHFRT as standard of care radiotherapy regimen

Hannah Clarke
“These findings reinforce isodose MHFRT as the standard of care, offering the same cancer control as conventional treatment but with fewer side effects than dose-escalated MHFRT,” says Amar U. Kishan, MD.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
FDA reports Urgent Device Field Correction notice for CVAC Aspiration System
March 21st 2025

FDA reports Urgent Device Field Correction notice for CVAC Aspiration System

Hannah Clarke
Calyxo has identified a new risk of injury when the CVAC System is used in patients with high viscosity fluid in their kidneys at the start of the procedure.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
FDA approves PET imaging product Gozellix for prostate cancer
March 20th 2025

FDA approves PET imaging product Gozellix for prostate cancer

Hannah Clarke
Gozellix – after radiolabeling with 68Ga – is indicated for PET imaging of PSMA positive lesions in men with prostate cancer who have suspected metastases and are candidates for initial definitive therapy and those who have suspected recurrence based on an elevated serum prostate-specific antigen level.
Trial launches of CBP/p300 inhibitor in mCRPC
March 20th 2025

Trial launches of CBP/p300 inhibitor in mCRPC

Hannah Clarke
Pocenbrodib is an oral, small molecule designed to inhibit the proteins CREBBP/EP300, which activate genes that promote cancer cell growth and proliferation.
© 2025 MJH Life Sciences

All rights reserved.